Research Study

 
News Articles for Research Study top ^
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives.
Sign-up for Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies investment picks
Kyungpook National University Hospital in South Korea Treats the First Patient in the 14 Country, 100 Site Global Study Study Designed to Support Registration in Major Liver Cancer Markets Worldwide LAWRENCEVILLE, N.J. , Sept.
Sign-up for Celsion Announces Enrollment of First Patient in Global Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer investment picks
http://media.marketwire.com/attachments/201212/109000_36797_HP_Blue_RGB_72_MD.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1151474&ProfileId=051205&sourceType=1 PALO ALTO, CA --
Sign-up for Annual Study Reveals Average Cost of Cyber Crime Escalates 96 Percent to $12.7 Million per Organization investment picks
Migalastat Successfully Meets Both Co-Primary Endpoints of Comparability to Enzyme Replacement Therapy (ERT) on Both Key Measures of Kidney Function CRANBURY, N.J., Aug.
Sign-up for Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012 investment picks
SANTA ROSA, Calif., Oct.
Sign-up for TriVascular Announces First Patient Enrollment in the LIFE (Least Invasive Fast-Track EVAR) Study investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0977674001&sourceType=1 http://www.ccnmatthews.com/logos2/Semafo.gif MONTREAL, QUEBEC --
Sign-up for SEMAFO Provides Its Observations to Orbis' Notice of AGM and Updated Scoping Study investment picks
2014/11/6
Horizonte Minerals plc - Infill drilling commenced to support a feasibility study on the Araguaia Nickel Project Canada NewsWire LONDON , Nov.
Sign-up for Horizonte Minerals plc - Infill drilling commenced to support a feasibility study on the Araguaia Nickel Project investment picks
These Studies and Genomic Health's First Liquid Biopsy Study in Bladder Cancer To Be Presented at 2014 Society of Urologic Oncology Annual Meeting, December 3-5 Authors: Isabell Sesterhenn , Timothy Brand , Inger Rosner , Joel Moncur , Amina Ali , Yongmei Chen , Nan Zhang , Athanasios Tsiatis , Dejan Knezevic , Tara Maddala , H.
Sign-up for Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact Study To Be Published in European Urology and Urology Practice, Respectively investment picks
PRINCETON, New Jersey and BANGALORE, India , October 27, 2014 /PRNewswire/ -- Infosys and the Institute for Advanced Study (IAS) today announced a new endowment fund that will be used to support visiting scientists and scholars advance their research at the world-renowned institute in Princeton, New Jersey .
Sign-up for Infosys Donates $2 Million to the Institute for Advanced Study to Create a New Fund for Memberships investment picks
Reflecting a proactive stance to ready their firms for the future, independent registered investment advisors (RIAs) are taking steps in the areas of leadership, talent and business legacy planning, according to the results of the latest Independent Advisor Outlook Study (IAOS) released today by Schwab Advisor Services at its annual IMPACT ® 2014 conference.
Sign-up for Schwab Study Finds RIAs Addressing Leadership and Talent to Prepare Firms for the Future investment picks
Clovis Oncology (NASDAQ:CLVS) today announced preliminary Phase 2 results from the ARIEL2 ( A ssessment of R ucaparib I n Ovarian Canc e r Tria l ) study and updated results from the ongoing Phase 1/2 monotherapy study of rucaparib.
Sign-up for Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy investment picks
Results from First Clinical Study Using NGS-based Proprietary Liquid Biopsy Platform to Detect Presence of Breast Cancer Also Will Be Presented REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent Clinical Validation Study of Oncotype DX® in DCIS Breast Cancer at 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) investment picks
2014/9/24
Schwab Advisor Services released the results from a first-of-its kind survey today examining the career paths of independent registered investment advisors (RIAs) and the attributes of the profession that attract talent into its ranks.
Sign-up for Schwab RIA Talent Study Reveals Industry Attributes That Attract Advisors to RIA Profession investment picks
2014/10/2
Three out of four people are not aware that dense breast tissue increases a woman’s risk of developing breast cancer, 1, 2 according to a new global study from GE Healthcare exploring perspectives on breast cancer with an emphasis on understanding awareness around dense breast tissue and the most common symptoms of breast cancer.
Sign-up for GE Healthcare Study: Most People Unaware that Women with High Breast Density are 4 to 5 Times More Likely to Develop Breast Cancer 1 2 investment picks
Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR) CRANBURY, N.J., and SAN DIEGO, Oct.
Sign-up for Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011 investment picks
DM2 ENABLE Study data to be presented today at the 19th Annual Meeting of the International Federation for the Surgery of Obesity and Metabolic Disorders ST.
Sign-up for EnteroMedics Announces Three Year Diabetes, Hypertension and Weight Loss Data from the Maestro® RC System DM2 ENABLE Study investment picks
2014/9/11
Genzyme , a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today positive interim results from the second year of the extension study of Lemtrada ™ (alemtuzumab) for multiple sclerosis.
Sign-up for At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies investment picks
Pfizer Inc. (NYSE:PFE) announced today it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086 (rLP2086), with a licensed quadrivalent human papillomavirus vaccine (HPV4), at IDWeek 2014™ in Philadelphia.
Sign-up for Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Research Study
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Storage  |  Next: Research Subscription